

Supplementary Table I. Genes whose low expression was associated with increased risk of recurrence and death in METABRIC TNBC patients.

HR of low to high expression													
Gene	HR for death	95% CI of HR	p-value	HR for recurrence	95% CI of HR	p-value	Gene	HR for death	95% CI of HR	p-value	HR for recurrence	95% CI of HR	p-value
RASSF5	3.024	1.951-4.796	<0.0001	2.652	1.747-4.099	<0.0001	PTPRO	2.167	1.412-3.385	0.0004	2.158	1.428-3.308	0.0002
DOCK2	2.853	1.852-4.466	<0.0001	2.428	1.609-3.706	<0.0001	CD52	2.167	1.426-3.323	0.0003	2.081	1.390-3.137	0.0004
HLA-DMB	2.618	1.718-4.034	<0.0001	2.667	1.773-4.056	<0.0001	HLA-DQA1	2.164	1.423-3.323	0.0003	2.115	1.413-3.190	0.0003
CLEC12A	2.612	1.665-4.229	<0.0001	2.309	1.507-3.628	<0.0001	LAT2	2.162	1.418-3.341	0.0003	1.952	1.301-2.958	0.0012
IFNG	2.588	1.640-4.223	<0.0001	2.448	1.582-3.899	<0.0001	ZNF831	2.148	1.388-3.394	0.0005	2.092	1.373-3.254	0.0005
TRAT1	2.576	1.667-4.064	<0.0001	2.542	1.669-3.943	<0.0001	PSMB10	2.145	1.401-3.345	0.0004	2.105	1.396-3.225	0.0003
CD3D	2.563	1.678-3.950	<0.0001	2.243	1.492-3.393	0.0001	HLA-DRA	2.139	1.406-3.292	0.0004	2.197	1.464-3.331	0.0001
STAT4	2.495	1.620-3.902	<0.0001	2.148	1.422-3.281	0.0003	IL10RA	2.138	1.401-3.306	0.0004	2.047	1.363-3.113	0.0005
S1PR4	2.416	1.565-3.801	<0.0001	2.421	1.591-3.752	<0.0001	LAPTM5	2.127	1.394-3.293	0.0004	1.954	1.304-2.965	0.0011
PREX1	2.408	1.567-3.768	<0.0001	2.214	1.467-3.389	0.0001	PRAMEF17	2.124	1.396-3.269	0.0004	1.910	1.278-2.879	0.0016
ZBED2	2.402	1.553-3.799	<0.0001	2.320	1.525-3.602	<0.0001	P2RY13	2.116	1.380-3.303	0.0005	1.899	1.261-2.901	0.0020
HLA-DMA	2.398	1.575-3.693	<0.0001	2.667	1.773-4.056	<0.0001	IL2RB	2.106	1.376-3.269	0.0006	2.024	1.345-3.085	0.0007
CD53	2.396	1.564-3.730	<0.0001	2.387	1.582-3.655	<0.0001	CXCL9	2.095	1.375-3.225	0.0006	2.075	1.380-3.149	0.0004
GBP5	2.389	1.558-3.728	<0.0001	2.326	1.539-3.571	<0.0001	VCAM1	2.087	1.342-3.334	0.0009	2.096	1.372-3.276	0.0005
CD3G	2.361	1.544-3.670	<0.0001	2.186	1.453-3.333	0.0001	TBXAS1	2.075	1.358-3.217	0.0007	1.969	1.311-2.991	0.0010
CTSS	2.355	1.540-3.660	<0.0001	2.133	1.419-3.243	0.0002	CYSLTR1	2.060	1.339-3.237	0.0009	1.929	1.277-2.965	0.0017
CXCR6	2.316	1.502-3.647	0.0001	2.211	1.456-3.419	0.0002	AKNA	2.048	1.340-3.182	0.0009	1.950	1.290-2.977	0.0013
KIR2DL3	2.313	1.473-3.746	0.0002	2.214	1.438-3.501	0.0002	HLA-DOA	2.025	1.329-3.124	0.0010	1.871	1.249-2.831	0.0023
CD226	2.306	1.491-3.650	0.0001	2.154	1.420-3.327	0.0003	CD300LF	2.010	1.303-3.166	0.0014	1.906	1.258-2.942	0.0022
KIR3DL3	2.303	1.506-3.567	0.0001	2.279	1.512-3.509	<0.0001	PARVG	2.006	1.317-3.093	0.0012	1.897	1.265-2.871	0.0019
LPXN	2.294	1.495-3.577	0.0001	2.084	1.382-3.185	0.0004	SPCS3	1.941	1.275-2.992	0.0019	1.754	1.175-2.641	0.0059
DOCK10	2.293	1.499-3.559	0.0001	2.288	1.516-3.497	<0.0001	SLC52A1	1.940	1.264-3.036	0.0023	1.974	1.308-3.032	0.0011
SLCO2B1	2.285	1.496-3.540	0.0001	2.117	1.411-3.210	0.0003	GZMH	1.929	1.256-3.022	0.0025	1.907	1.262-2.931	0.0020
SLAMF7	2.285	1.482-3.597	0.0002	2.062	1.363-3.173	0.0005	PITPNM2	1.928	1.259-3.000	0.0024	1.777	1.179-2.701	0.0058
ARHGAP30	2.279	1.486-3.557	0.0001	2.315	1.531-3.559	<0.0001	KLRD1	1.928	1.263-2.986	0.0022	1.926	1.281-2.934	0.0015
APOBEC3G	2.277	1.484-3.562	0.0001	2.319	1.532-3.577	<0.0001	C8orf31	1.919	1.263-2.949	0.0022	1.763	1.179-2.660	0.0056
KIR3DL1	2.275	1.461-3.629	0.0002	2.404	1.562-3.790	<0.0001	PLCL2	1.887	1.238-2.914	0.0030	1.895	1.260-2.888	0.0021
CD6	2.274	1.487-3.524	0.0001	2.122	1.409-3.233	0.0003	CCDC28A	1.883	1.226-2.937	0.0037	1.993	1.318-3.059	0.0010
SASH3	2.260	1.476-3.518	0.0002	2.160	1.432-3.307	0.0002	WNT2	1.879	1.230-2.917	0.0034	1.847	1.231-2.808	0.0029
PVRIG	2.255	1.461-3.531	0.0002	2.109	1.391-3.240	0.0004	AGAP2	1.861	1.222-2.866	0.0037	1.868	1.247-2.824	0.0024
PCED1B	2.252	1.464-3.506	0.0002	2.061	1.364-3.145	0.0006	INSRR	1.854	1.216-2.866	0.0040	1.665	1.112-2.518	0.0132
PRKCB	2.251	1.466-3.512	0.0002	2.129	1.430-3.261	0.0003	RCBTB2	1.853	1.205-2.900	0.0048	1.715	1.137-2.618	0.0099
PLEK	2.251	1.472-3.485	0.0002	2.186	1.450-3.333	0.0002	PRKCH	1.850	1.213-2.861	0.0041	1.764	1.175-2.683	0.0060
SEL1L	2.250	1.453-3.541	0.0003	2.137	1.405-3.298	0.0003	ADARB2-AS1	1.845	1.205-2.877	0.0046	1.832	1.217-2.803	0.0036
HCLS1	2.247	1.473-3.473	0.0002	2.065	1.377-3.130	0.0004	PPM1M	1.801	1.184-2.772	0.0058	1.706	1.140-2.578	0.0093
VAV1	2.245	1.457-3.534	0.0002	2.276	1.498-3.529	<0.0001	PLBD1	1.788	1.171-2.767	0.0070	1.945	1.292-2.965	0.0014
ITK	2.239	1.458-3.499	0.0002	2.157	1.425-3.317	0.0002	REM1	1.784	1.166-2.773	0.0073	1.811	1.204-2.765	0.0042
GZMA	2.232	1.456-3.477	0.0002	2.183	1.444-3.348	0.0002	RFTN1	1.776	1.163-2.751	0.0077	1.755	1.168-2.672	0.0066
EV12B	2.218	1.450-3.434	0.0002	2.033	1.350-3.088	0.0007	KCNE1	1.774	1.165-2.724	0.0074	1.806	1.206-2.725	0.0041
CD83	2.214	1.441-3.467	0.0002	2.079	1.380-3.183	0.0004	LCP1	1.762	1.163-2.683	0.0076	1.792	1.200-2.689	0.0044
DEF6	2.191	1.431-3.403	0.0003	1.963	1.304-2.990	0.0012	TPK1	1.749	1.150-2.692	0.0088	1.736	1.158-2.628	0.0074
BTN3A2	2.181	1.422-3.404	0.0003	2.077	1.379-3.171	0.0004	RASGEF1A	1.734	1.136-2.683	0.0106	1.972	1.308-3.014	0.0011
IGFALS	2.175	1.426-3.362	0.0003	1.976	1.318-2.990	0.0009	HHEX	1.733	1.134-2.677	0.0109	1.739	1.156-2.642	0.0078
FLT3LG	2.172	1.417-3.382	0.0003	1.975	1.312-3.010	0.0010	FBXO47	1.689	1.096-2.648	0.0171	1.671	1.102-2.579	0.0154

HR, hazard ratio; CI, confidence interval. Hazard ratio was adjusted for age at diagnosis (continuous) and NPI (continuous). The corresponding 95% CI and p-value was based on likelihood ratio test. Sample size n = 233. Genes were listed in descending order of HR values for death.

Supplementary Table II. Genes whose high expression was associated with increased risk of recurrence and death in METABRIC TNBC patients.

Gene	HR of high to low expression					
	HR for death	95% CI of HR	p-value	HR for recurrence	95% CI of HR	p-value
<i>LINC00943</i>	2.106	1.380-3.256	0.0005	1.967	1.311-2.981	0.0010
<i>EXD2</i>	2.096	1.370-3.264	0.0006	1.947	1.296-2.967	0.0013
<i>USP30</i>	2.066	1.349-3.212	0.0008	1.986	1.318-3.031	0.0010
<i>TMEM59L</i>	2.046	1.333-3.200	0.0009	2.002	1.330-3.062	0.0008
<i>SNORA65</i>	2.044	1.339-3.164	0.0009	1.836	1.225-2.777	0.0032
<i>PHOX2A</i>	2.036	1.326-3.186	0.0010	1.863	1.239-2.859	0.0027
<i>CAPN14</i>	2.007	1.309-3.131	0.0013	1.919	1.273-2.938	0.0017
<i>NCBP2</i>	2.006	1.313-3.104	0.0012	1.815	1.210-2.747	0.0039
<i>DCAF4</i>	2.004	1.315-3.083	0.0012	1.857	1.240-2.799	0.0026
<i>FFAR1</i>	1.974	1.292-3.058	0.0016	2.007	1.336-3.055	0.0008
<i>CYTH2</i>	1.964	1.287-3.048	0.0017	1.896	2.264-2.882	0.0019
<i>LBX2</i>	1.963	1.291-3.002	0.0016	2.012	1.343-3.032	0.0007
<i>DNAAF3</i>	1.954	1.282-3.002	0.0018	1.878	1.253-2.837	0.0023
<i>DNAJB7</i>	1.941	1.280-2.965	0.0018	1.848	1.239-2.774	0.0026
<i>FAM204A</i>	1.920	1.255-2.991	0.0025	2.054	1.359-3.162	0.0006
<i>ZNF271P</i>	1.904	1.256-2.906	0.0024	1.781	1.193-2.669	0.0048
<i>PTRHD1</i>	1.894	1.244-2.920	0.0028	1.861	1.241-2.823	0.0026
<i>DNM3</i>	1.889	1.246-2.890	0.0027	2.173	1.452-3.283	0.0002
<i>SCAF4</i>	1.850	1.212-2.865	0.0042	1.713	1.144-2.593	0.0088
<i>MAP3K9</i>	1.848	1.205-2.870	0.0048	1.941	1.287-2.960	0.0015
<i>DOLK</i>	1.848	1.208-2.869	0.0045	1.839	1.221-2.807	0.0034
<i>TSEN34</i>	1.825	1.197-2.816	0.0050	1.715	1.147-2.585	0.0086
<i>CA9</i>	1.802	1.185-2.729	0.0062	1.702	1.136-2.539	0.0102
<i>NCAPG</i>	1.793	1.170-2.793	0.0071	1.645	1.094-2.501	0.0165
<i>GRWD1</i>	1.757	1.153-2.713	0.0085	1.742	1.161-2.644	0.0072
<i>RCAN3</i>	1.755	1.146-2.716	0.0095	1.795	1.193-2.728	0.0049
<i>H2BC9</i>	1.749	1.143-2.705	0.0099	1.876	1.245-2.855	0.0026
<i>TMEM190</i>	1.734	1.135-2.687	0.0108	1.738	1.155-2.649	0.0078
<i>MRGBP</i>	1.703	1.118-2.627	0.0129	1.592	1.064-2.408	0.0237
<i>ENO1</i>	1.664	1.099-2.529	0.0163	1.582	1.061-2.365	0.0246
<i>PLIN3</i>	1.633	1.074-2.494	0.0218	1.619	1.081-2.438	0.0195
<i>DONSON</i>	1.619	1.060-2.508	0.0258	1.526	1.016-2.316	0.0417
<i>PDCD6IPP2</i>	1.609	1.058-2.466	0.0262	1.651	1.103-2.489	0.0147
<i>PRADC1</i>	1.605	1.044-2.494	0.0311	1.686	1.113-2.584	0.0136
<i>SKA1</i>	1.601	1.045-2.486	0.0304	1.482	0.986-2.249	0.0586

HR, hazard ratio; CI, confidence interval. Hazard ratio was adjusted for age at diagnosis (continuous) and NPI (continuous). The corresponding 95% CI and p-value was based on likelihood ratio test. Sample size n = 233. Genes were listed in descending order of HR values for death.